Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee. Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| HROW | HARROW, INC. | 2026-05-22 14:59:46 | 33 | 0.03 | 0.09 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HROW | 0001360214 | HARROW, INC. | US4158581094 | 529900AP4LIRLNV8A089 | 450567010 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 1A BURTON HILLS BLVD | NASHVILLE | TN | — | UNITED STATES | US | 615.733.4731 | 1A BURTON HILLS BLVD, NASHVILLE, TN | 1A BURTON HILLS BLVD, NASHVILLE, TN | HARROW HEALTH, INC. | Pharmaceutical Industry | 2012 | Mark L. Baum | — | http://www.harrow.com/ | 1,004,000,000 | 37,269,400 | 37,275,107 | Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee. Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing. | 2026-05-21 17:12:02 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 1,004,000,000 | 326,000,000 | 48.0826 | 37,229,705 | 1,575,534 | 4.4189 |
| 2024 | 678,000,000 | 214,000,000 | 46.1207 | 35,654,171 | 291,529 | 0.8244 |
| 2023 | 464,000,000 | 305,000,000 | 191.8239 | 35,362,642 | 5,394,893 | 18.0023 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Amir H. Shojaei | Chief Scientific Officer | 2025 | 441,346 | — | 0 | 225,000 | 5,712 | 1,342,627 |
| Mark L. Baum | Chief Executive Officer | 2025 | 754,910 | — | 22,294,873 | 542,491 | 14,000 | 23,606,274 |
| Francis W. Mullery | President, Chief Executive Officer | 2025 | 129,808 | — | 0 | 53,260 | 0 | 1,237,692 |
| Andrew R. Boll | President, Chief Financial Officer | 2025 | 505,259 | — | 10,169,924 | 258,258 | 14,000 | 10,947,441 |
| John P. Saharek | President, Chief Executive Officer | 2025 | 475,614 | — | 0 | 237,807 | 14,000 | 727,421 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 373 |
| 2024 | 382 |
| 2023 | 315 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 272,303,000 | 199,614,000 | 130,193,000 |
| Cost Of Revenue | 67,934,000 | 49,245,000 | 39,640,000 |
| Gross Profit | 204,369,000 | 150,369,000 | 90,553,000 |
| Research And Development Expenses | 20,940,000 | 12,230,000 | 6,652,000 |
| General And Administrative Expenses | 152,914,000 | 129,064,000 | 83,090,000 |
| Operating Expenses | 173,854,000 | 141,547,000 | 90,122,000 |
| Operating Income | 30,515,000 | 8,822,000 | 431,000 |
| Net Income | -5,139,000 | -17,481,000 | -24,411,000 |
| Earnings Per Share Basic | -0.14 | -0.49 | -0.75 |
| Earnings Per Share Diluted | -0.14 | -0.49 | -0.75 |
| Weighted Average Shares Outstanding Basic | 36,760,461 | 35,650,714 | 32,616,777 |
| Weighted Average Shares Outstanding Diluted | 36,760,461 | 35,650,714 | 32,616,777 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 72,927,000 | 47,247,000 | 74,085,000 |
| Marketable Securities Current | — | — | 8,681,000 |
| Accounts Receivable | 110,895,000 | 20,147,000 | 15,146,000 |
| Inventories | 13,523,000 | 10,702,000 | 10,867,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 2,128,000 | 3,410,000 | 1,753,000 |
| Total Assets Current | 211,750,000 | 189,651,000 | 139,482,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 3,260,000 | 3,734,000 | 3,521,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 187,732,000 | 199,320,000 | 172,682,000 |
| Total Assets | 399,482,000 | 388,971,000 | 312,164,000 |
| Accounts Payable | 35,355,000 | 38,762,000 | 21,424,000 |
| Deferred Revenue | 788,000 | 44,000 | 75,000 |
| Short Term Debt | — | 23,877,000 | 21,201,000 |
| Other Liabilities Current | — | 0 | 89,000 |
| Total Liabilities Current | 96,302,000 | 91,343,000 | 49,344,000 |
| Long Term Debt | 250,000,000 | 262,737,000 | 246,717,000 |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 251,089,000 | 228,331,000 | 192,409,000 |
| Total Liabilities | 347,391,000 | 319,674,000 | 241,753,000 |
| Common Stock | 37,000 | 35,000 | 35,000 |
| Retained Earnings | -156,524,000 | -151,385,000 | -133,904,000 |
| Accumulated Other Comprehensive Income | — | — | — |
| Total Shareholders Equity | 52,446,000 | 69,652,000 | 70,766,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 1,915,000 | 1,850,000 | 1,530,000 |
| Share Based Compensation Expense | 12,502,000 | 17,619,000 | 15,696,000 |
| Other Non Cash Income Expense | -13,000 | — | — |
| Change In Accounts Receivable | -5,010,000 | 80,232,000 | 30,344,000 |
| Change In Inventories | 2,821,000 | -165,000 | 4,326,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | -924,000 | 6,072,000 | 5,647,000 |
| Change In Accounts Payable | -4,608,000 | 37,498,000 | 31,795,000 |
| Change In Other Liabilities | 936,000 | 4,046,000 | 1,425,000 |
| Cash From Operating Activities | 43,864,000 | -22,202,000 | 3,840,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | 5,510,000 | — |
| Acquisition Of Property Plant And Equipment | 887,000 | 1,595,000 | 1,460,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -5,460,000 | -33,164,000 | -152,553,000 |
| Tax Withholding For Share Based Compensation | — | 1,205,000 | 11,273,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | — | 64,520,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | 244,375,000 | — | 55,879,000 |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -12,724,000 | 28,528,000 | 126,528,000 |
| Change In Cash | 25,680,000 | -26,838,000 | -22,185,000 |
| Cash At End Of Period | 72,927,000 | 47,247,000 | 74,085,000 |
| Income Taxes Paid | 93,000 | 374,000 | — |
| Interest Paid | 18,718,000 | 20,594,000 | 18,887,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -0.14 | -0.49 | -0.75 |
| Price To Earnings Ratio | -350 | -68.4694 | -14.9333 |
| Earnings Growth Rate | -71.4286 | -34.6667 | 47.0588 |
| Price Earnings To Growth Ratio | 4.9 | 1.9751 | -0.3173 |
| Book Value Per Share | 1.417 | 1.9438 | 2.1587 |
| Price To Book Ratio | 34.5792 | 17.2602 | 5.1882 |
| Ebitda | 21,049,000 | 7,529,000 | -1,557,000 |
| Enterprise Value | 1,978,335,589 | 1,435,448,454.7 | 559,140,902.4 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 4.7668 | 4.1149 | 3.786 |
| Capital Expenditures | 1,441,000 | 2,063,000 | 1,565,000 |
| Free Cash Flow | 42,423,000 | -24,265,000 | 2,275,000 |
| Return On Equity | -0.098 | -0.251 | -0.345 |
| One Year Beta | 1.5192 | 2.17 | 0.5743 |
| Three Year Beta | 1.4194 | 0.8705 | 0.6204 |
| Five Year Beta | 1.0126 | 0.984 | 0.8841 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| SILVERNAIL LAUREN P | Director | 2026-05-18 | 1,000 | A | 1,000 |
| Graves Adrienne L | Director | 2026-05-18 | 1,000 | A | 1,000 |
| Shojaei Amir | CHIEF SCIENTIFIC OFFICER | 2026-05-15 | 10,000 | A | 10,000 |
| BOLL ANDREW R. | PRESIDENT AND CFO | 2026-05-14 | 3,500 | A | 814,679 |
| BAUM MARK L | Director, CHIEF EXECUTIVE OFFICER | 2026-05-14 | 10,000 | A | 2,996,130 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 2026-03-31 | 476,213 | 13,500 | 35.275 |
| EverSource Wealth Advisors, LLC | 2026-03-31 | 2,327 | 66 | 35.2576 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 2026-03-31 | 1,375,810 | 39,019 | 35.26 |
| BANK OF AMERICA CORP /DE/ | 2026-03-31 | 3,334,821 | 94,578 | 35.26 |
| ALLIANCEBERNSTEIN L.P. | 2026-03-31 | 1,452,213 | 29,637 | 49 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| BUFFALO FUNDS | 2026-03-31 | Institutional Class | BUIOX | 27,083 | 954,946.58 | 1.5578 |
| BUFFALO FUNDS | 2026-03-31 | Investor Class | BUFOX | 27,083 | 954,946.58 | 1.5578 |
| iSHARES TRUST | 2026-03-31 | iShares U.S. Pharmaceuticals ETF | IHE | 92,131 | 3,248,539.06 | 0.3247 |
| AQR Funds | 2026-03-31 | Class R6 | QSMRX | 3,586 | 126,442.36 | 0.0758 |
| AQR Funds | 2026-03-31 | Class N | ASMNX | 3,586 | 126,442.36 | 0.0758 |